Evidence map›Paper›PMID 19440353›Full record

ArticlePloS one2009

Expression of a mutant p53 results in an age-related demographic shift in spontaneous lung tumor formation in transgenic mice.

Wenrui Duan, Li Gao, Xin Wu, Erinn M Hade, Jian-Xin Gao, Haiming Ding, Sanford H Barsky, Gregory A Otterson, Miguel A Villalona-Calero

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Alterations in the mutagenicity and mutation spectrum induced by benzo[a]pyrene instilled in the lungs of gpt delta mice of various ages.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2015
    Article
  6. Article
  7. Mutant p53 gain-of-function in cancer.Cold Spring Harbor perspectives in biology · 2010
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Wenrui DuanComprehensive Cancer Center, The Ohio State University College of Medicine and Public Health, Columbus, Ohio, United States of America.
Li Gao
Xin Wu
Erinn M Hade
Jian-Xin Gao
Haiming Ding
Sanford H Barsky
Gregory A Otterson
Miguel A Villalona-Calero
The Ohio State University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
NCI NIH HHS CA76970NCI NIH HHS P30 CA016058NCI NIH HHS P30CA16058
6 · The paper itself

Abstract

backgroundMutations in the P53 gene are among the most common genetic abnormalities in human lung cancer. Codon 273 in the sequence-specific DNA binding domain is one of the most frequently mutated sites. METHODOLOGY: To investigate the role of mutant p53 in lung tumorigenesis, a lung specific p53(273H) transgenic mouse model was developed. Rates of lung cancer formation in the transgenic animals and their littermates were evaluated by necropsy studies performed in progressive age cohorts ranging from 4 to 24 months. In order to establish the influence of other common genetic abnormalities in lung tumor formation in the animals, K-Ras gene mutation and p16INK4a (p16) promoter methylation were evaluated in a total of 281 transgenic mice and 189 non-transgenic littermates. PRINCIPAL

findingsAt the age extremes of 4-12 and 22-24 months no differences were observed, with very low prevalence of tumors in animals younger than 12 months, and a relatively high prevalence at age 22 months or older. However, the transgenic mice had a significant higher lung tumor rate than their non-transgenic counterparts during the age of 13-21 months, suggesting an age-related shift in lung tumor formation induced by the lung-specific expression of the human mutant p53. Histopathology suggested a more aggressive nature for the transgenic tumors. Older mice (>13 months) had a significantly higher rate of p16 promoter methylation (17% v 82%). In addition, an age related effect was observed for K-Ras codons 12 or 13 mutations, but not for codon 61 mutations. CONCLUSIONS/SIGNIFICANCE: These results would suggest that the mutant p53(273H) contributes to an acceleration in the development of spontaneous lung tumors in these mice. Combination with other genetic and epigenetic alterations occurring after the age of 13 months is intimately linked to its oncogenic potential.

Indexed as

Gene Expression RegulationAgingAnimalsCell CycleCell DifferentiationCell ProliferationCyclin-Dependent Kinase Inhibitor p16DNA MethylationGenes, rasImmunohistochemistryLung NeoplasmsMiceMice, TransgenicMutationPromoter Regions, GeneticTumor Suppressor Protein p53Cyclin-Dependent Kinase Inhibitor p16Tumor Suppressor Protein p53

Identifiers

PMID19440353
PMCPMC2680060
OpenAlexW2095113485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.